Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

[1]  M. Tormo,et al.  A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia , 2021, Cancer.

[2]  H. Döhner,et al.  Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. , 2020, The New England journal of medicine.

[3]  A. Bacigalupo,et al.  Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives , 2020, Mediterranean journal of hematology and infectious diseases.

[4]  M. Tormo,et al.  Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? , 2020, Leukemia.

[5]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[6]  H. Einsele,et al.  Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? , 2020, Blood.

[7]  J. Novak,et al.  Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. , 2020, Blood.

[8]  B. Stevens,et al.  Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. , 2019, Blood advances.

[9]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[10]  B. Djulbegovic,et al.  Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia , 2019, Haematologica.

[11]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Delpierre,et al.  Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey , 2018, Haematologica.

[13]  H. Dombret,et al.  How and when to decide between epigenetic therapy and chemotherapy in patients with AML. , 2017, Hematology. American Society of Hematology. Education Program.

[14]  G. Laurent,et al.  Improved outcome for AML patients over the years 2000–2014 , 2017, Blood Cancer Journal.

[15]  E. Estey,et al.  Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality , 2017, JAMA oncology.

[16]  C. Récher,et al.  Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia , 2017, Oncotarget.

[17]  S. Gore,et al.  Selecting initial treatment of acute myeloid leukaemia in older adults. , 2017, Blood reviews.

[18]  Lars Bullinger,et al.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[20]  L. Ellison.  Increasing survival from leukemia among adolescents and adults in Canada: A closer look. , 2016, Health reports.

[21]  C. Schiffer,et al.  The artful management of older patients with acute myeloid leukemia , 2016, Expert review of hematology.

[22]  B. Ko,et al.  Genetic alterations and their clinical implications in older patients with acute myeloid leukemia , 2016, Leukemia.

[23]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[24]  J. Laurent,et al.  Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network , 2014, American journal of hematology.

[25]  Bernd Holleczek,et al.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. , 2014, The Lancet. Oncology.

[26]  E. Estey,et al.  Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.

[27]  M. Gobbi,et al.  Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making , 2013, Leukemia.

[28]  H. Kantarjian,et al.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.

[29]  Paul C. Lambert,et al.  Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .

[30]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[31]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[32]  G. Ehninger,et al.  A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.

[33]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[34]  H. Dombret,et al.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia , 2008, Haematologica.

[35]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[36]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.